Browsing Tag
Retatrutide
7 posts
Eli Lilly (LLY) reclaims a $1tn valuation as Wall Street bets on its next weight-loss drug
Eli Lilly reclaimed a $1 trillion valuation at a record high as Wall Street prices in retatrutide, its next-gen obesity drug, and the GLP-1 metabolic platform thesis.
MHRA weight-loss drug raid exposes black-market risk behind Britain’s slimming jab boom
Weight-loss jabs are booming, and criminals are following demand. The MHRA raid shows how illicit supply is becoming a patient safety threat.
Is Eli Lilly (LLY) building the obesity drug supply chain nobody else can easily match?
Lilly’s obesity pipeline needs industrial muscle. Its $4.5bn Indiana bet shows why manufacturing may decide the next GLP-1 race.
Eli Lilly (NYSE: LLY) bets on oral GLP-1 Foundayo and retatrutide to reclaim its $1tn valuation
Eli Lilly (NYSE: LLY) launched Foundayo, the world's first oral GLP-1 for obesity, in April 2026 and reports Q1 earnings April 30. Full pipeline and risk analysis for retail investors.
Lilly selects Lehigh Valley, Pennsylvania for obesity drug manufacturing plant
Lilly is building a $3.5B injectable medicine facility in Pennsylvania to scale retatrutide. Find out how this reshapes the obesity drug market and U.S. supply.
What’s next after Zepbound? Inside Eli Lilly and Company’s pipeline beyond GLP-1
Discover which drugs Eli Lilly and Company is betting on after Zepbound, including oral GLP-1 pills and next-generation incretins that could redefine the global obesity treatment market.
Can high-dose GLP-1 therapies reshape obesity care—or are we nearing the biological ceiling?
Are high-dose GLP-1 drugs like Wegovy 7.2mg and Zepbound 15mg unlocking better weight loss—or just more side effects? Here’s what the latest data suggests.